Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer Sparano, J. A., Zhao, F., Martino, S., Ligibel, J., Saphner, T., Wolff, A. C., Sledge, G. W., Perez, E. A., Wood, W. C., Davidson, N. E. AMER ASSOC CANCER RESEARCH. 2015

View details for DOI 10.1158/1538-7445.SABCS14-S3-03

View details for Web of Science ID 000356730200020